Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Tandutinib. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDGFRB known ✓ | P09619 | 19/20 | 0.93 |
| ▸ | FLT3 known ✓ | P36888 | 7/20 | 0.93 |
| ▸ | KIT known ✓ | P10721 | 6/20 | 0.93 |
| ▸ | CSF1R | P07333 | 4/20 | 0.93 |
| ▸ | PLK4 | O00444 | 1/20 | 0.93 |
| ▸ | GAK | O14976 | 1/20 | 0.93 |
| ▸ | EPHB6 | O15197 | 1/20 | 0.93 |
| ▸ | STK10 | O94804 | 1/20 | 0.93 |
| ▸ | EGFR | P00533 | 1/20 | 0.93 |
| ▸ | NTRK1 | P04629 | 1/20 | 0.93 |
| ▸ | LCK | P06239 | 1/20 | 0.93 |
| ▸ | FGFR1 | P11362 | 1/20 | 0.93 |
| ▸ | SRC | P12931 | 1/20 | 0.93 |
| ▸ | PDGFRA | P16234 | 1/20 | 0.93 |
| ▸ | FLT1 | P17948 | 1/20 | 0.93 |
| ▸ | FGFR2 | P21802 | 1/20 | 0.93 |
| ▸ | FGFR4 | P22455 | 1/20 | 0.93 |
| ▸ | FGFR3 | P22607 | 1/20 | 0.93 |
| ▸ | AXL | P30530 | 1/20 | 0.93 |
| ▸ | FLT4 | P35916 | 1/20 | 0.93 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Tandutinib SCHEMBL927974 | 0.96 | PDGFRB (1.00) | PDGFRBFLT3KITCSF1RPLK4 | |
| Tandutinib SCHEMBL29393910 | 0.96 | PDGFRB (1.00) | PDGFRBFLT3KITCSF1RPLK4 | |
| Tandutinib SCHEMBL2478362 | 0.96 | PDGFRB (0.98) | PDGFRBFLT3KITCSF1RPLK4 | |
| SCHEMBL13330466 | 0.96 | PDGFRB (1.00) | PDGFRBFLT3KITCSF1RPLK4 | |
| SCHEMBL13330462 | 0.93 | PDGFRB (1.00) | PDGFRBFLT3KITCSF1RPLK4 | |
| SCHEMBL13524739 | 0.91 | PDGFRB (0.90) | PDGFRBFLT3KITCSF1RPLK4 | |
| SCHEMBL13529590 | 0.90 | PDGFRB (0.89) | PDGFRBFLT3KITCSF1RPLK4 | |
| SCHEMBL13330482 | 0.89 | PDGFRB (0.88) | PDGFRBFLT3KITCSF1RPLK4 | |
| SCHEMBL29460355 | 0.89 | PDGFRB (1.00) | PDGFRBFLT3KITCSF1RPLK4 | |
| SCHEMBL317630 | 0.89 | PDGFRB (1.00) | PDGFRBFLT3KITCSF1RPLK4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20150133460-A1 | LACTATE SALT OF 4-[6-METHOXY-7-(3-PIPERIDIN-1-YL-PROPOXY)QUINAZOLIN-4-YL]PIPERAZINE-1-CARBOXYLIC ACID(4-ISOPROPOXYPHENYL)-AMIDE AND PHARMACEUTICAL COMPOSITIONS THEREOF FOR THE TREATMENT OF CANCER AND OTHER DISEASES OR DISORDERS | MILLENNIUM PHAMACEUTICALS, INC. (US) | 2015-05-14 | — | — | US | disclosed |
| EP-2370417-A2 | LACTATE SALT OF 4-[6-METHOXY-7-(3-PIPERIDIN-1-YL-PROPOXY)QUINAZOLIN-4-YL]PIPERAZINE-1-CARBOXYLIC ACID(4-ISOPROPOXYPHENYL)-AMIDE AND PHARMACEUTICAL COMPOSITIONS THEREOF FOR THE TREATMENT OF CANCER AND OTHER DISEASES OR DISORDERS | Millennium Pharmaceuticals, Inc. (US) | 2011-10-05 | — | — | EP | disclosed |
| US-20100273808-A1 | LACTATE SALT OF 4-[6-METHOXY-7-(3-PIPERIDIN-1-YL-PROPOXY)QUINAZOLIN-4-YL]PIPERAZINE-1-CARBOXYLIC ACID(4-ISOPROPOXYPHENYL)-AMIDE AND PHARMACEUTICAL COMPOSITIONS THEREOF FOR THE TREATMENT OF CANCER AND OTHER DISEASES OR DISORDERS | Millennium Pharmaceticals, Inc. (US) | 2010-10-28 | — | — | US | disclosed |
| WO-2010059239-A2 | LACTATE SALT OF 4-(6-METHOXY-7-(3-PIPERIDIN-1-YL-PROPOXY)QUINAZOLIN-4-YL]PIPERAZINE-1-CARBOXYLIC ACID(4-ISOPROPOXYPHENYL)-AMIDE AND PHARMACEUTICAL COMPOSITIONS THEREOF FOR THE TREATMENT OF CANCER AND OTHER DISEASES OR DISORDERS | MILLENNIUM PHARMACEUTICALS, INC (US) | 2010-05-27 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100273808-A1 | LACTATE SALT OF 4-[6-METHOXY-7-(3-PIPERIDIN-1-YL-PROPOXY)QUINAZOLIN-4-YL]PIPERAZINE-1-CARBOXYLIC ACID(4-ISOPROPOXYPHENYL)-AMIDE AND PHARMACEUTICAL COMPOSITIONS THEREOF FOR THE TREATMENT OF CANCER AND OTHER DISEASES OR DISORDERS | GLS, GLS2, GOT2 | PDGFRB 107/4885FLT3 257/4885KIT 625/4885 |
| US-20150133460-A1 | LACTATE SALT OF 4-[6-METHOXY-7-(3-PIPERIDIN-1-YL-PROPOXY)QUINAZOLIN-4-YL]PIPERAZINE-1-CARBOXYLIC ACID(4-ISOPROPOXYPHENYL)-AMIDE AND PHARMACEUTICAL COMPOSITIONS THEREOF FOR THE TREATMENT OF CANCER AND OTHER DISEASES OR DISORDERS | GLS, GLS2, GOT2 | PDGFRB 107/4885FLT3 257/4885KIT 625/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.